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 ABSTRACT 1 
 2 
 3 
Rationale: Identifying latently infected individuals is crucial for tuberculosis elimination. We 4 
evaluated for the first time the performance of a new type of interferon- release assays, 5 
QuantiFERON-TB Plus that includes an additional antigen tube (TB2) stimulating both CD4+ 6 
and CD8+ T-cells in contacts of tuberculosis patients. 7 
 8 
Materials and Methods: Contacts were screened for latent tuberculosis infection by 9 
tuberculin-skin-test, QuantiFERON-TB Plus (QFT-Plus) and QuantiFERON-TB Gold in 10 
Tube (QFT-GIT).   11 
 12 
Results:  In 119 TB contacts, the overall agreement between QFT-Plus and QFT-GIT was 13 
high, with a Cohen’s kappa of 0.8. Discordant results were found in 12 subjects with negative 14 
QFT-GIT and positive QFT-Plus results. In analyses of markers of tuberculosis exposure and 15 
tests results, the average time spent with the index case was the strongest risk factor for both 16 
tests’ positivity. The difference in interferon- production between the two antigen tubes 17 
(TB2-TB1) was used as an estimate of CD8+ stimulation provided by the TB2. TB2-TB1 18 
values >0.6ml/IU were significantly associated with proximity to the index case and European 19 
origin. 20 
 21 
Conclusion: QuantiFERON-Plus has a stronger association with surrogate measures of TB 22 
exposure than QFT-GIT in adults screened for LTBI. Interferon- response in the new antigen 23 
tube used an indirect estimate of specific CD8+ response correlates with increased M. 24 
tuberculosis exposure  suggesting a possible role in identifying individuals with recent 25 
infection. 26 
 27 
 28 
  29 
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INTRODUCTION   37 
Despite the progress recently made in tuberculosis (TB) control at a global level, the decline in 38 
TB incidence is much slower than that needed to achieve TB elimination by 2050[1]. 39 
Identifying and treating symptom-free people who are truly latently infected with 40 
M.tuberculosis (Mtb) is key to achieving this[2][3]. The current global burden of latent 41 
infection is uncertain, although it has been suggested that one third of the world’s population 42 
may be latently infected with Mtb[4].  43 
Although they show no sign of disease, individuals with latent tuberculosis infection (LTBI) 44 
are at risk of reactivating and up to 10% of them may develop active disease in their lifetime[5]. 45 
This risk is highest in the first 2 years following infection. Preventive treatment of recently-46 
infected individuals reduces this[6]. However isoniazid preventive therapy is not optimal for a 47 
large-scale implementation program, and the current LTBI diagnostic tests – Tuberculin Skin 48 
Test (TST) and Interferon- release assay (IGRAs)- have significant limitations. TST may be 49 
falsely positive due to sensitization by environmental mycobacteria and BCG-vaccination[7]. 50 
In recent decades IGRAs measuring the INF- concentration after in vitro whole blood 51 
stimulation with peptides from the RD-1 region of the Mtb genome were developed to improve 52 
specificity of the diagnosis[8]. IGRAs are a useful indicator of Mtb exposure as their specificity 53 
is very high (97%)[9]. However, like TST, they lose sensitivity in immune-compromised 54 
individuals and children[10][11]; they identify both recent and past infection and they are poor 55 
at predicting LTBI subjects who are at greater risk of developing disease (positive predictive 56 
value IGRA 2,7% TST 1,5%)[12]. As a result when currently available diagnostic tests are used 57 
to guide the administration of preventive therapy, the number needed to treat to prevent one 58 
case of TB is too high to allow a large-scale preventive program. Different approaches have 59 
been described in the literature to help discriminate those at greater risk of active TB 60 
development. The use of INF- response to the latency antigen Heparin-Binding-61 
Haemoagglutinin (HBHA)[13][14], immunoprofiling[15][16], gene expression pattern (i.e. IL-62 
13 and AIRE)[17][18] and proportion of peripheral blood monocytes[19] have been studied as 63 
possible biomarkers for incipient TB. However all of these approaches are still confined to 64 
research fields and currently have minimal impact on patient management.  65 
QuantiFERON-TB Plus (QFT-Plus) is a new generation of QTF-Gold In Tube (QFT-GIT) [5] 66 
that includes an additional antigen tube (TB2). The TB1 tube contains ESAT-6- and CFP-10-67 
derived peptides (TB-7.7, present in QFT-GIT, has been removed), designed to elicit cell-68 
mediated immune responses from CD4+ T-helper lymphocytes. TB2 contains new   peptides 69 
   
able to stimulate IFN-γ production by both CD4+ and CD8+ T-cells [20].  70 
Evidence supports the important contribution of CD8+ T-cells in host defense against Mtb by 71 
both cytokine secretion and cytotoxic activity[21]. Firstly a positive correlation between 72 
specific CD8+ T cells and increased mycobacterial load has been found in peripheral blood ex 73 
vivo[22]. Day et al. reported that more than 60% of individuals with smear-positive TB had 74 
detectable CD8+ T cells response compared with 38% and 20% of smear-negative and LTBI 75 
respectively. Consistent with this paradigm a higher prevalence of Mtb-specific CD8+ T cells 76 
have been reported in smear-positive versus smear-negative patients and in PTB compared with 77 
EPTB[23]. In addition, a positive correlation between the CD8+ T cells response against TB 78 
antigens and a recent exposure to Mtb have been found. Recent contacts of active TB patients, 79 
independent of their response to QTF, have a greater CD8+ T cell response compared to other 80 
study groups (active TB patients, health care workers, BCG-vaccinated healthy controls)[24]. 81 
This is in agreement with findings observed in a cattle model where a CD8+ T cell response is 82 
present at the onset of infection.[25]  83 
The INF- release assays currently in use primarily elicit a CD4+ response, but emerging data 84 
provide a good rationale for also measuring   specific CD8+ T cell responses and in particular 85 
to further investigate the association between CD8+ T cells and risk of disease progression.   86 
In the present study we evaluate the performance characteristics of the new QFT-Plus assay in 87 
TST-positive contacts with recent exposure to people with confirmed active tuberculosis, 88 
assessing the use of QFT-Plus head-to-head with the previous QFT-GIT. In addition, we 89 
investigate for the first time the significance and the possible use of the CD8+ INF- response 90 
provided by the second newly-added antigen tube.   91 
 92 
MATERIAL AND METHOD 93 
Study setting and participants  94 
We conducted a cross-sectional study at Villa Marelli-Niguarda Hospital. TB incidence in 95 
Milan is of 16.6 new cases per 100.000 persons year (in 2011)[26], three-times higher than the 96 
Italian national average. From November 2014 to June 2015 we prospectively recruited TST-97 
positive (TST5mm) contacts of notified active TB cases sent by the local public health 98 
services to be screened for LTBI.  99 
Contacts were excluded if aged less than 18 years old, a previous positive TST was documented, 100 
preventive TB treatment was prescribed or past TB history was reported. Informed written 101 
consent was obtained from each study subject.  102 
Contacts reporting mild or severe immunosuppression (diabetes mellitus, chronic kidney 103 
   
disease, HIV, malignancy, immunosuppressive medications) were included.  104 
The study was approved by the Ethics committee*.  105 
Contact screening strategy was based on the National Institute of Clinical Excellence TB 106 
guidelines 2011 [27] and Italian guidelines which recommends retesting those with positive 107 
TST results using an IGRA as confirmatory test. At the contact’s first visit health status was 108 
established by clinical examination and chest X-ray. Further information on the country of birth, 109 
immigration status, nature of the contact to the source case, BCG-vaccination status (if details 110 
were unclear inspection of BCG-vaccination scar was performed by trained healthcare-111 
assistants), and clinical history were obtained through personal interviews. When clinical 112 
suspicion persisted, chest CT scan and sputum sample analyses were requested.  113 
All patients also underwent testing in line with recommended routine screening as part of 114 
contact investigation. Thus, TST-positive contacts who tested negative to a first QFT-GIT 115 
analysis were retested with QFT-GIT after 10-12 weeks to exclude delayed conversion.  116 
Blood samples were obtained for QFT-GIT, QFT-Plus and HIV testing from all subjects 117 
providing informed consent. QFT-GIT currently in use in clinical practice was performed at 118 
Niguarda Microbiology service while QFT-Plus was carried out in the Emerging Bacterial 119 
Pathogen Laboratory at San Raffaele Hospital. The QFT-Plus and QFT-GIT tests were 120 
performed according to the manufacturer’s instructions. Peripheral blood samples for the two 121 
tests were obtained simultaneously directly into the QFT tubes and processed within 4 h. Test 122 
interpretation for both QFT-Plus and QFT-GIT was performed according to the manufacturer’s 123 
instruction manual. QFT-GIT results were recorded positive if the antigen response were >0.35 124 
ml/UI above the negative control response.  Positivity (antigen response >0.35 ml/UI above the 125 
negative control response) of a single antigen tube (either TB1 or TB2) was sufficient to score 126 
the QFT-Plus test as positive. 127 
 128 
Ascertainment of exposure  129 
We assessed different factors as surrogate markers of Mtb exposure. The aggregate exposure 130 
time of contacts prior to the diagnosis of their respective source case was established by 131 
recording the extent of the contact during a typical week. TB contacts were categorized 132 
according to proximity to the index case[28]: we considered them to be “high proximity” if 133 
contacts and case patient were sharing routinely the same bedroom and lower proximity if 134 
contacts and case patient were sleeping in a different bedroom in the same house or in a different 135 
                                                        
* (GO/URC/ER/mm prot. n.82/DG, 26 Feb 2010 and successive amendments) 
   
house. Sputum smear positivity of the index case was also assessed as TB case related risk 136 
factor.  137 
Statistical Analysis 138 
The agreement between QFT-GIT and QFT-Plus was evaluated by computing the overall 139 
percent of concordant results and Cohen's kappa coefficient with 95% Confidence Interval (CI).  140 
Univariate logistic regression and backward stepwise multivariate logistic regression models 141 
were used to identify factors associated with positive test results. The variables considered in 142 
the analyses were: gender, whether the country of birth was an endemic area of TB and whether 143 
it was European, BCG vaccination, immunocompromised status, smear status of index case, 144 
average time spent per week with the index case and place of sleeping with respect to the index 145 
case. The same analysis was performed for the variable denoting whether the differences 146 
between QFT-Plus TB2 and QFT-Plus TB1 was greater than the cut-off 0.6 IU/ml (as described 147 
in the Results). The level of significance considered was 5%. All statistical analyses were done 148 
using R statistical software (version 3.2.3). 149 
 150 
RESULTS  151 
A total of 119 Mtb-exposed individuals with positive TST (5mm) were investigated. Of these, 152 
39 were contacts of a smear-negative culture-positive TB case, and 69 of a smear-positive 153 
culture positive index case. Participants had a median age of 38 years (25-75 percentile: 30-154 
79), more than half (n=61, 51.26%) were non-European-born, 82 (78.85%) were BCG-155 
vaccinated and 11 (9.24%) were immunocompromised subjects. Demographic characteristics 156 
of the cohort are shown in the Table 1. 157 
Agreement between QFT-Plus and QFT-GIT 158 
Sixty-eight out of 119 (57.1%) contacts were QFT-Plus positive. 64 subjects were positive in 159 
both antigen tubes, 2 were positive to TB1 only and 2 were positive to TB2 only. Fifty-six of 160 
119 TST-positive contacts were positive to QFT-GIT. The overall agreement between the two 161 
IGRAs was high, with a Cohen’s kappa of 0.8 (95% CI 0.69-0.91). The two tests gave 162 
concordant results for 107 (89.9%) subjects (see Table 2). Discordant results were found in 12 163 
subjects: they all scored negative to the QFT-GIT and positive to the QFT-Plus. Discordant 164 
results between the two IGRAs included the 4 contacts with a single tube QFT-Plus positivity. 165 
Moreover, contacts with IGRAs discordant results had overall low INF- responses but not as 166 
   
low to be considered borderline results (median: TB1-Nil=0.83 IU/ml, TB2-Nil=0.73 IU/ml).  167 
The characteristics of subjects with discordant results are shown in Table 3. Only one of the 12 168 
contacts with QFT-Plus positive and QFT-GIT negative results had a TST response less than 169 
10mm (7mm). Globally, the median TB1 QFT-Plus antigen IFN-γ level (TB1-Nil) was 0.74 170 
IU/ml, whereas the median TB2 QFT-Plus antigen IFN-γ level (TB2-Nil) was 0.67 IU/ml, as 171 
reported in Table 2.  172 
 As per the Italian guidelines, contacts of TB cases with initial positive TST results who tested 173 
negative to a first QFT-GIT analysis, were re-tested with QFT-GIT at 10-12 weeks. At the post-174 
exposure follow-up, two contacts converted to QFT-GIT positive results. Both of them were 175 
part of the 12 contacts who initially showed QFT-plus-positive/QFT-GIT-negative discordant 176 
results (Table 2). One of them had a strong QFT-GIT positivity (>10 ml/IU) at 10 weeks post-177 
exposure follow-up; while the second case reported a QFT-GIT of 0.5 ml/UI after 6 month of 178 
isoniazid preventive therapy (decision to treat was based on the strong TST positivity and the 179 
proximity of contact with the index case). In both cases the TB2 INF- response was greater 180 
than that found in TB1. 181 
Independent predictors of QFT-Plus and QFT-GIT positivity  182 
For both QFT-GIT and QFT Plus test, the univariate odds ratios of being positive for different 183 
possible surrogate markers of increasing exposure to Mtb is presented in Table 4.  Contacts 184 
reporting that they had spent more than 12 hours per day with the index case were significantly 185 
more likely to be both QFT-GIT and QFT-Plus positive, compared to contacts spending 1-4 186 
hours per day with the index case. For a subject with an exposure time > 12 hours, the odds of 187 
a positive test were 6 times higher by QFT-GIT and 14 times higher by QFT-Plus. Both test 188 
results were significantly more likely to be positive in subjects with closer sleeping proximity 189 
to the patient (same house versus different house). The odds of being QFT-GIT positive for 190 
subjects sleeping in the same house of the index case were approximately 4 times (different 191 
rooms: 3.79; same room: 3.98) higher than for those sleeping in a different house, whereas their 192 
odds of being QFT-Plus positive were approximately 6 times (different rooms: 5.78; same 193 
room: 5.65). The results of the backward stepwise multivariate logistic regression analysis are 194 
presented in Table 5. Only the variable indicating whether a contact spent on average more than 195 
12h per day with the index case remained significantly associated with a positive QFT-GIT 196 
result (OR: 4.63; 95% CI: 2.05-10.47) and a positive QFT-Plus result (OR: 6.98; 95% CI: 2.86-197 
17.02). 198 
   
Predictors for CD8 T-cell stimulation  199 
To assess the specific contribution of CD8+ T cells, we subtracted the quantitative value of the 200 
first antigen tube expressed in IU/ml (TB1), which stimulates the CD4+ population only, from 201 
the value provided by the second antigen tube (TB2), in which a combined CD4+ and CD8+ T 202 
cell stimulation occurred. We used a difference of 0.6 IU/ml to define positive results in order 203 
to reduce the bias of the intrinsic variability of the test[29].  Eighteen contacts out of 119 204 
(15.13%) had a difference between TB2 and TB1 greater than 0.6 IU/ml. Univariate logistic 205 
regression was used to identify factors associated with differences between TB2 and TB1 > 0.6 206 
IU/ml (Table 4). This method identified sleeping in the same room compared to sleeping in 207 
different houses (OR: 4.34; 95%CI: 1.37-13.81), and European origin (OR: 3.24; 95%CI: 1.07-208 
9.75) to be to be significantly positively associated with a greater TB2 response. These 209 
associations persisted in the multivariate analysis, shown in Table 6.   210 
 211 
DISCUSSION 212 
We provide the first evaluation of QFT-Plus assay alongside the previous version QFT-GIT in 213 
a cohort of TST-positive contacts of active TB cases.  214 
Positive results from QFT-Plus were associated with surrogate markers of increasing recent 215 
exposure to Mtb. Paired comparison between QFT-GIT and QFT-Plus shows an overall good, 216 
but not complete agreement. Furthermore the overall INF- response in QFT-Plus 217 
positive/QFT-GIT negative contacts was in the majority of cases out of the uncertainty zone 218 
for test interpretation[29], suggesting that differences between the tests are not due to test 219 
variability. Of note, the disagreement between the two tests all goes in the same direction, with 220 
a total of 12 TST-positive contacts positive with the new QFT-Plus and negative to QFT-GIT. 221 
With no gold standard for LTBI to refer to, it is difficult to assess whether the discordant results 222 
found during the contact screening are attributable to the higher sensitivity of the QFT-Plus 223 
test. If the TST were taken as the reference test for LTBI, this would mean that the proportion 224 
of TST-positive contacts confirmed by the IGRA test is increased by 17% when using the QFT-225 
Plus compared to QFT-GIT. False positivity with TST is mainly due to sensitization by BCG-226 
vaccination[7]. QFT-Plus specificity in a BCG-vaccinated population has not been investigated 227 
yet, however we found that QFT-Plus is not associated with BCG-vaccination both in univariate 228 
and multivariate analysis. Moreover only one of the 12 contacts with QFT-Plus positive and 229 
QFT-GIT negative result had a TST response less than 10mm while another showed an intense 230 
TST positivity which is less likely to be the result of previous vaccination[7] 231 
Recent findings suggest that the discordance between IGRAs and TST in recently-exposed 232 
   
individuals may be related to delayed conversion of IGRAs relative to TST[30][31]. In this 233 
study we find that most of the discordant cases (QFT-GIT negative/QFT-Plus positive) show 234 
intense TST positivity; moreover, we reported a shorter period of conversion for QFT-Plus 235 
compared to QFT-GIT at least in two individuals of our cohort. These results suggest that QFT-236 
Plus may be more sensitive in detecting new or recent infection with Mtb than the QFT-GIT. 237 
Our data demonstrate that risk factors for test positivity were the same for both IGRAs. QFT-238 
Plus showed stronger associations with surrogate measure of recent exposure than QFT-GIT 239 
both in univariate and multivariate analysis The average time spent per day with the index case 240 
had the strongest association with test positivity.  241 
We investigated for the first time the difference in INF- production between the two QFT-Plus 242 
tubes and surrogate markers of increasing exposure. TB2-TB1 differential values were used as 243 
an indirect estimate of specific CD8+ stimulation with the newly added antigens. A cut-off value 244 
was set at 0.6 ml /IU in order to exclude small variations due to inter-test variability[29]. 245 
Positive TB2-TB1 differences (>0.6ml/IU) were significantly associated with sleeping 246 
proximity to the index case with an odds ratio comparable to the one obtained in the analysis 247 
of QFT-GIT and QFT-Plus (sleeping in the same room compared to sleeping in different houses 248 
OR: 4.34; 95%CI: 1.37-13.81). Moreover, European origin (OR: 3.24; 95%CI: 1.07-9.75) was 249 
significantly associated with TB2-TB1 > 0.6ml/IU, while it was not statistically significant for 250 
the QFT-GIT and the QFT-Plus results.  251 
As individuals from European countries have a low risk for Mtb exposure, these findings are 252 
consistent with the hypothesis that the difference in response between the TB1 and TB2 tubes 253 
could be used as a surrogate marker of recent exposure (linked to the specific index case 254 
exposure), and not to previous cumulative Mtb exposure. A recent flow-cytometry study 255 
reported a positive correlation between the CD8+ T cells response against the QFT-GIT antigens 256 
and recent exposure to Mtb in contacts of active TB patients compared to controls (active TB 257 
patients, health care workers, BCG-vaccinated healthy controls)[24].  258 
Tests currently used for Mtb infection diagnosis do not reflect CD8+ T cell cytokine 259 
production[32], however results reported in previous flow-cytometry studies and our own 260 
findings provide a strong rationale for measurement of Mtb-specific CD8+ T cell response. If 261 
validated, this may prove to be a surrogate marker of recent infection which, having the highest 262 
risk of progression to active TB, may enable QFT-Plus to distinguish recent infection from long 263 
lasting reactivity and hence allow better targeted delivery of preventive therapy. 264 
 Mtb-specific CD8+ T cell have been more frequently detected in individuals with active TB 265 
when compared with LTBI and correlated with increasing antigenic burden[21][23][22][33] 266 
   
[34], suggesting that the presence of CD8+ T cells in a small proportion of latently infected 267 
individuals may be predictive of Mtb active replication and more likely disease progression[22]. 268 
Consistent with these results, in a previous study we found that the difference in responses 269 
between the QFT-Plus tubes may positively correlate with increasing antigenic load in active 270 
TB patients, as it was significantly more common in smear-positive versus smear-negative 271 
active TB patients[35]. In the present study, we observed a greater TB2 antigen response (TB2-272 
TB1 difference >0.6ml/UI) in 18 (15.13%) individuals, all QFT-Plus positive. We speculate 273 
that the small subgroup of latently infected contacts with TB2-TB1 difference >0.6ml/UI have 274 
higher antigenic burden. However, to date, we do not have the tools to directly assess Mtb 275 
antigenic burden, as current LTBI tests rely on the (indirect) measurement of a specific immune 276 
response.  277 
Our study has limitations. The foremost of these was the sample size, which comprises 119 278 
subjects. Moreover because of the lack of gold standard tests for LTBI, we were unable to 279 
adequately resolve the discordance between QFT-GIT and QFT-Plus. In addition, TST-280 
negative contacts were not recruited in our sample and a full evaluation of the test would benefit 281 
of their presence. Finally, the positive predictive value of the test and of the new parameter, the 282 
difference between the two antigen tubes, needs to be properly assessed in a longitudinal cohort. 283 
However, this would require follow-up of a large cohort (as incident TB is an uncommon event) 284 
and could only be performed in groups who are not eligible for chemoprophylaxis. 285 
To our knowledge, our study is the first evaluation of QFT-Plus assay among recent contacts 286 
of TB cases. Although limited by the small sample size, our data show that QFT-Plus in contact 287 
screening has an improved performance compared to QFT-GIT and suggests a role for the 288 
differential value between the two tubes as a proxy for recent infection. Larger prospective 289 
studies are needed to assess the positive predictive value of the test and the possible role of the 290 
differential value between the two antigens tube as marker for recent infection.  291 
In conclusion, the difference between the two antigen tubes, used as an indirect estimate of 292 
specific CD8+ activation, is associated with factors indicating increased Mtb exposure, 293 
suggesting that this might identify individuals at greater risk of progression to active TB. 294 
QFT-plus shows stronger association with surrogate measures of exposure compared to QFT-295 
GIT and therefore seems at least as accurate as QFT-GIT in the setting of contact screening.  296 
 297 
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Table1: Demographic characteristics 
 Number % 
Sex (n=119)   
Male 63 52.9% 
Female 56 47.1% 
Estimated incidence of TB in country of birth° (n=119) 
0-50 per 100000 person-year 48 40.4% 
>50 per 100000 person-year 71 59.7% 
Country of birth (n=119)   
European 58 48.7% 
NON European 61 51.3 
BCG* vaccination (n=104)   
No 22 21.1% 
Yes 82 78.8% 
Smear status of index case (n=108) 
Negative 39 36.1% 
Positive 69 63.9% 
Time spent with the index case (hours per day) (n=108) 
1-4 27 25% 
5-8 25 23.1% 
9-12 9 8.3% 
>12 47 43.5% 
Sleeping proximity to the index case (n=108) 
Different house 61 56.5% 
Different rooms 19 17.6% 
Same room 28 25.9% 
Immunocompromised§ (n=119)   
No 108 90.8% 
Yes 11 9.2% 
° As per WHO Report 2014 
*BCG bacilli Clamette-Guérin 
§ Causes of immunosuppression: diabetes mellitus (6), chronic kidney disease (0), HIV (2), malignancy (2), 
immunosuppressive medications (1)
   
 
 
Table 2: Test results 
QFT-GIT 
results 
QFT Plus results 
 
Positive 
results per 
tube 
 
QTF Plus IFN- γ concentrations 
(IU/ml)* 
Negative Positive 
 
TB1 TB2 
 
TB1-Nil TB2-Nil 
Negative (n=63) 51 (80.95%) 12 (19.05%) 
 
10° 10§ 
 
0.01 (-0.01;0.17) 0.04 (0;0.23) 
Positive (n=56) 0 56 (100%) 
 
56 56 
 10.60 
(2.94;16.57) 
11.00 (3.32;17.75) 
Total (n=119) 51 (42.86%) 68 (57.14%) 
 
66 66 
 
0.74 (0.01;9.65) 0.67 (0.04;8.94) 
*median (25-75 percentile) 
° 2 were positive to TB1 only 
§ 2 were positive to TB2 only 
 
 
   
Table 3: QFT-Plus and QFT-GIT discordant results    
Sample 
no 
BCG 
scar 
 TST** 
QFT-
GIT 
QFT-
Plus 
TB1° 
QFT-
Plus 
TB2§ 
Index 
case 
smear 
status 
Relation to Index 
case 
Immunosuppression 
C1 Yes 20 Neg 1.83 0.51 Pos 
Household, 
primary caregiver 
Prednisone treatment 
C11 Yes 7 Neg* 0.49 0.83 Pos Boyfriend No 
C15 No 21 Neg* 0.11 0.48 Pos 
Employer (index 
case: house-made) 
No 
C17 Yes 10 Neg 0.38 0.41 Neg Household, sister No 
C39 Yes 20 Neg 0.83 0.88 Pos 
Hospital close 
contact (sharing 
the same room) 
Cancer 
C53 Yes 20 Neg 0.3 0.58 Pos 
Colleague, every 
day ride at work 
No 
C63 Yes 16 Neg 0.74 0.67 Neg Household No 
C69 Yes 14 Neg 0.52 0.29 Pos Household No 
C75 Yes 11 Neg 0.81 0.9 Pos Household No 
C78 No 11 Neg 1.88 1.93 Pos 
Colleague (sharing 
the same room) 
No 
C91 Yes 14 Neg 0.36 0.1 Neg Household No 
C98 Yes 20 Neg 1.65 1.14 Pos Household Pregnant 
° TB1-Nil 
§ TB2-Nil 
* Repeated test by QFT-IT at follow up converted to positive  
** Diameter of induration in mm 
   
Table 4: Univariate logistic regressions 
 QFT Positive  QFT Plus Positive  TB2-TB1>0.6 
 OR (95% CI) p-value 
 OR (95% CI) p-value  OR (95% CI) p-value 
Age 1.02 (1.00;1.05) 0.09  1.02 (1.00;1.05) 0.101  1.03 (1.00;1.07) 0.053 
Sex         
Male 1   1   1  
Female 0.73 (0.35;1.5) 0.387  0.76 (0.37;1.57) 0.458  1.49 (0.55;4.10) 0.435 
Estimated incidence of TB per 100000 person-year in country of birth°    
0-50  1   1   1  
 >50  1.44 (0.69;3.01) 0.333  1.63 (0.78;3.42) 0.197  0.82 (0.30;2.25) 0.7 
Country of birth         
NON European 1   1   1  
European 0.84(0.41;1.73) 0.635  0.74 (0.36;1.54) 0.428  3.24 (1.07;9.75) 0.037 
BCG* vaccination          
No 1   1   1  
Yes 2.04 (0.75;5.53) 0.161  2.26 (0.87;5.89) 0.096  0.98 (0.25;3.87) 0.978 
Smear status of index case         
Negative 1   1   1  
Positive 1.12 (0.51;2.47) 0.780  1.39 (0.63;3.07) 0.413  1.29 (0.41;4.03) 0.662 
Time spent with the index case (hours per day)     
1-4 1   1   1  
5-8 1.65 (0.48;5.67) 0429  3.23 (0.97;10.72) 0.055  3.55 (0.34;36.53) 0.288 
9-12 2.8 (0.57;13.83) 0.206  4.37 (0.89;21.61) 0.070  7.43 (0.59;94.26) 0.122 
>12 6.78 (2.28;20.16) 0.0006  14.78(4.62;47.25) 5.6e-06  7.03 (0.85;58.2) 0.071 
Sleeping proximity to the index case     
Different house 1   1   1  
Different rooms 3.79 (1.29;11.14) 0.015  5.78 (1.71;19.52) 0.005  0.51 (0.06;4.52) 0.545 
Same room 3.98 (1.55;10.23) 0.004  5.65 (2.00;15.97) 0.001  4.34 (1.37;13.81) 0.013 
Immunocompromised        
No 1   1   1  
Yes 0.62 (0.17;2.22) 0.459  1.35 (0.37;4.88) 0.649  0.54 (0.06;4.46) 0.563 
° As per WHO Report 2014 
*BCG bacilli Clamette-Guérin  
   
Table 5.  Backward stepwise multivariate logistic regressions for predicting QFT-GIT or 
QFT Plus Positivity 
 QFT-GIT Positive  QFT Plus Positive 
 OR (95% CI) p-value  OR (95% CI) p-value 
Time spent with the index case (hours per day)     
1-12 1   1  
>12 4.63 (2.05; 10.47) 0.0002  6.98 (2.86; 17.02) 1.98e-05 
° As per WHO Report 2014 
 
 
   
Table 6. Backward stepwise multivariate logistic regression for predicting TB2-TB1>0.6  
 OR (95% CI) p-value 
Country of birth   
NON European 1  
European 3.46 (1.03;11.69) 0.0453 
Sleeping proximity to the index case  
No same room 1  
Same room 5.90 (1.83;18.97) 0.0029 
 
   
 
